Latest News and Press Releases

First ever approved Peptide Receptor Radionuclide Therapy in CanadaNeuroendocrine tumors are rare malignancies that affect approximately 12,000-15,000 Canadians2 SAINT-GENIS-POUILLY, France, Feb. ...

Novel small molecule FF-10158 targets integrin alphavbeta3 (avβ3) and alphavbeta5 (avβ5) receptors Expands theragnostic pipeline  Potential broad application in the detection and treatment of highly...

SAINT-GENIS-POUILLY, France, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a Novartis company and leader in nuclear medicine...

SAINT-GENIS-POUILLY, France, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a Novartis company and a leader in nuclear medicine...

First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients LUTATHERA® marks first FDA Approval for a Peptide Receptor...

SAINT-GENIS-POUILLY, France, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a leader in nuclear medicine theragnostics, today...

SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...

SAINT-GENIS-POUILLY, France, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...

$3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETs Recent Highlights: Sales for the third quarter of 2017 increased 39%...

SAINT-GENIS-POUILLY, France, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...